Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$3.6 million.

  • Lineage Cell Therapeutics' Cash from Operations rose 3751.51% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.4 million, marking a year-over-year increase of 1044.59%. This contributed to the annual value of -$23.1 million for FY2024, which is 1916.26% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Cash from Operations stood at -$3.6 million for Q3 2025, which was up 3751.51% from -$5.5 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Cash from Operations' 5-year high stood at $21.9 million during Q1 2022, with a 5-year trough of -$11.2 million in Q1 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' median Cash from Operations value was -$5.8 million (recorded in 2024), while the average stood at -$4.6 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first surged by 39504.31% in 2022, then tumbled by 15132.4% in 2023.
  • Lineage Cell Therapeutics' Cash from Operations (Quarter) stood at -$5.9 million in 2021, then plummeted by 41.38% to -$8.3 million in 2022, then grew by 27.51% to -$6.0 million in 2023, then dropped by 5.43% to -$6.3 million in 2024, then skyrocketed by 43.02% to -$3.6 million in 2025.
  • Its Cash from Operations stands at -$3.6 million for Q3 2025, versus -$5.5 million for Q2 2025 and -$4.9 million for Q1 2025.